Atlas Trials

A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors

Clinical trial NCT01962896 · TERMINATED

Trial details

NCT number
NCT01962896
Sponsor
Theodore Laetsch
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsed / Recurrent Germ Cell Tumors
Start date
2014-01-08
Primary completion
2017-06-13
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.